| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2014: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2013: ¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
|
|---|
| Outline of Final Research Achievements |
Mifepristone is known as a steroid receptor antagonist and is clinically used as an anti-cancer agent. This study aimed to determine whether mifepristone influences insulin sensitivity and adiponectin secretion both in in vivo and in vitro. First, we explored the effects of mifepristone, on metabolic functions in obese mice. When these mice were fed mifepristone, they exhibited a marked improvement in insulin sensitivity, and attenuated hepatic injury, compared with mice that received only the high-fat diet. Intriguingly, mifepristone-treated mice showed significantly elevated plasma adiponectin levels. Second, we tested the effects of mifepristone on differentiated adipocytes in vitro. When adipocytes were treated with mifepristone, adiponectin was upregulated at both mRNA and protein levels. These results uncover a possibility that long term administration of mifepristone leads to non-obese non-alcoholic fatty liver disease, associated with overeating or dyslipidemia.
|
